Phase 3 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 18 years or older
- People who have been diagnosed with prostate cancer confirmed by a tissue sample (biopsy)
- People whose primary treatment was surgical removal of the prostate (radical prostatectomy)
- People whose surgery included a procedure to spare at least one of the nerve bundles near the prostate
- People whose cancer had not spread to lymph nodes or other parts of the body at the time of surgery, based on scans or other assessments
- People whose PSA blood test showed an undetectable level within six weeks after surgery, as defined by the local medical team
- People who had a minimum level of sexual function before surgery, measured by a specific questionnaire score of 40 or more out of 100 (confirm with trial site)
- People with low testosterone levels, confirmed by two separate blood tests showing specific hormone patterns, alongside normal or elevated levels of a hormone called LH (confirm with trial site for exact values)
Who may not be able to join:
- People who received any previous treatment for prostate cancer, such as hormone therapy, radiation therapy, or brachytherapy (having been on active surveillance is acceptable)
- People who have previously used testosterone therapy for any reason
- People whose removed prostate showed cancer that had spread to certain nearby structures, classified as stage pT3b or pT4 (confirm with trial site)
- People whose surgical specimen showed cancer cells at the edges of the removed tissue (positive surgical margins) with a high-grade cancer rating of ISUP grade 4 or 5
- People whose pelvic lymph nodes were removed during surgery and were found to contain cancer
- People with a history of male breast cancer or a liver tumour
- People with high blood pressure that is not well controlled
- People who have a general medical reason that makes testosterone therapy unsuitable for them (confirm with trial site)
- People who are allergic to any ingredient in the testosterone treatment or the placebo being used in this trial
- People who take blood-thinning medications known as vitamin K antagonists (such as warfarin)
- People with a body mass index (BMI) above 30 kg/m²
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Diederik Somford, MD, PhD, Canisius-Wilhelmina Hospital
Phone: +31243658190
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinically relevant (≥12 points) difference in the EPIC-26 sexual functioning domain score, 12 months after radical prostatectomy between groups.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.